Collaborate Disseminate
Biotechnology company Moderna has revealed more data from its now-completed Phase 3 COVID-19 vaccine trial. The vaccine is reportedly 94.1 percent effective at preventing COVID-19 and 100 percent effective at preventing severe cases of the disease. An … Continue reading Moderna says vaccine prevents severe COVID-19, files for FDA approval
A novel cancer vaccine is moving to Phase 1 human trials in the United States after promising results from animal studies showed encouraging efficacy and a robust safety profile. A new study describes the vaccine as producing complete responses in 90 p… Continue reading Experimental cancer vaccine passes animal tests, moves to human trials
AstraZeneca and the University of Oxford have presented the first interim data from their Phase 3 COVID-19 vaccine trial. The vaccine is safe, up to 90 percent effective, and significantly easier to distribute compared to other options requiring comple… Continue reading Oxford’s COVID-19 vaccine trial delivers encouraging interim results
Pfizer and BioNTech have announced their large Phase 3 COVID-19 vaccine trial is complete. The trial has reportedly met all its primary endpoints and the vaccine is claimed to be 95 percent effective.Continue ReadingCategory: Health & Wellbeing, Li… Continue reading Pfizer reports COVID-19 vaccine 95% effective as Phase 3 trial concludes
One of the big stories last week was the announcement of results from clinical trials that suggest a new COVID-19 vaccine from the German companies Pfizer and BioNTech is strongly effective in providing immunity from the virus. In the midst of what is for many countries the second spike of …read more
A week after Pfizer reported its COVID-19 vaccine is more than 90 percent effective, biotechnology company Moderna has revealed similar efficacy from its own novel vaccine candidate. Both vaccines use a still experimental mRNA technology but experts ar… Continue reading New “very impressive” Phase 3 COVID-19 vaccine results reported
Days after Pfizer revealed the first interim Phase 3 trial data for any COVID-19 vaccine, Russian authorities have announced their vaccine candidate is also demonstrating promising results. Experts are calling the Russian data encouraging, but also cau… Continue reading Russia claims COVID-19 vaccine success, mass vaccinations may begin soon
Pharmaceutical companies Pfizer and BioTech have announced the first data from their Phase 3 COVID-19 vaccine trial, claiming the experimental mRNA candidate is more than 90 percent effective in preventing symptomatic disease. Experts point out these i… Continue reading First Phase 3 COVID-19 vaccine trial data is promising, but hurdles remain
Researchers in the United Kingdom are set to undertake controversial human challenge trials to accelerate the testing of COVID-19 vaccines. The trials, planned to commence in January 2021, will initially begin by deliberately infecting young and health… Continue reading UK to begin trials infecting healthy volunteers with COVID in early 2021
The attack on eResearchTechnology potentially slowed down coronavirus research worldwide, and researchers suggest a nation-state actor could be behind the incident. Continue reading COVID-19 Clinical Trials Slowed After Ransomware Attack